HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC Leaves Supplement Industry Still Waiting For Shift Away From RCT Standard For Claims

This article was originally published in The Tan Sheet

Executive Summary

FTC's "standard is the same. There's not any per se lower standard for substantiation just because you position your product as a supplement," says agency attorney Michelle Rusk. Supplement industry stakeholders, though, argue that FTC has no basis to require RCTs for structure/function claims.

You may also be interested in...

Clinical Trials Recommended For Pamprin Botanicals PMS Claims After Challenge By Bayer

Focus Consumer Healthcare appeals NAD recommendation to pull or modify majority of express and implied claims on Pamprin Botanical product packaging, in advertising and Amazon listings challenged by Bayer Consumer.

Does FTC Health Ads Guide Read Like Rulemaking, Ignore Court Decisions On Requiring RCTs?

“I'm not sure they shouldn’t have done a notice of proposed rulemaking,” says attorney Claudia Lewis. From previous guidance, “the FTC has taken it a step in the different direction that you need robust scientific evidence, in their mind robust scientific evidence means clinical data.”

Xlear Admits Referencing Research, Avers Studies Support Saline Nasal Spray’s COVID-19 Efficacy

Firm responds to a complaint DoJ filed for FTC. Founder and president Nathan Jones continues criticism that FTC is attempting to silence research-backed advertising for alternatives to pharmaceuticals public health agencies promote for preventing or treating COVID-19.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts